





Pharmacy Formulary Updates for September 2024

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in September 2024:

| Drug Name | Tufts Health Public Plan Formulary |
|-------------------------------|------------------------------------|
| | Tufts Health Direct Formulary |
| Adbry | T3;PA;QL;SPP |
| Freestyle Libre 3 Plus sensor | T3;PA;QL |
| Myhibbin suspension | NF |
| Ojemda | T3;PA;QL |
| Omnipod 5 Intro Kit | T3;PA;QL |
| Omnipod 5 Pods | T3;PA;QL |
| Retevmo | T3;PA;SPP |
| Sitagliptin-metformin hcl | NF |
| Spevigo | T3;PA;QL |
| Xolremdi | NF;QL |